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OBJECTIVES We sought to determine the prognostic importance of mitral regurgitation (MR) in patients
undergoing percutaneous coronary intervention for acute myocardial infarction (AMI).
BACKGROUND Mitral regurgitation has been associated with a poor prognosis in patients treated with
thrombolytic therapy for AMI. The prognostic significance of MR in patients undergoing
mechanical reperfusion therapy for AMI is unknown.
METHODS Left ventriculography was performed during the index procedure in 1,976 (95%) of 2,082
non-shock patients enrolled in a prospective, multicenter, randomized trial of mechanical
reperfusion strategies in AMI. The severity of operator-assessed MR was divided into four
strata: none (n  1,726), mild (n  192), and moderate/severe (n  58).
RESULTS Patients with progressively more severe MR were older (p  0.0001), were more often
women (p  0.0001), and had higher Killip class (p  0.0007). More severe grades of MR
correlated with triple-vessel disease (p  0.0001) and lower left ventricular ejection fraction
(LVEF) as measured during the index procedure (p  0.0004). Increasingly severe MR was
strongly associated with a higher mortality at 30 days (1.4% vs. 3.7% vs. 8.6%, respectively;
p  0.0001) and at one year (2.9%, 8.5%, 20.8%, respectively; p  0.0001). By multivariate
analysis, the presence of even mild MR was an independent predictor of long-term mortality
(mild MR, relative risk [RR]  2.40, p  0.005; moderate/severe MR, RR  2.82, p 
0.006).
CONCLUSIONS Mitral regurgitation of any degree present on the baseline left ventriculogram during the
index procedure is a powerful, independent predictor of mortality in patients undergoing
mechanical reperfusion therapy for AMI. The presence of MR identifies high-risk patients in
whom close out-patient follow-up is warranted, and who may benefit from aggressive
adjunctive medical or surgical therapies. (J Am Coll Cardiol 2004;43:1368–74) © 2004 by
the American College of Cardiology Foundationd
D
n
i
g
s
H
g
e
o
p
M
I
Litral regurgitation (MR) is a frequent complication of
cute myocardial infarction (AMI) and has several etiologies
1). In the setting of AMI, mitral regurgitation is most
ommonly due to valvular dysfunction without structural
isease (2–4), may result from altered ventricular geometry
5–7), incomplete mitral leaflet coaptation, papillary muscle
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t003, accepted November 13, 2003.ysfunction, and regional wall motion abnormalities (4,8).
uring AMI, mitral regurgitation carries an adverse prog-
osis (9–13), and it has been associated with high mortality
n patients treated with fibrinolytic therapy (9,10). Emer-
ent percutaneous coronary intervention (PCI) has been
hown to improve the degree of MR at follow-up (14–17).
owever, the prognostic impact of MR in patients under-
oing primary PCI for AMI is unknown. We therefore
xamined the relationship between baseline MR and clinical
utcomes after primary PCI in a large prospective trial of
atients with AMI without cardiogenic shock.
ETHODS
n the Controlled Abciximab and Device Investigation to
ower Late Angioplasty Complications (CADILLAC)rial, 2,082 patients of any age with AMI within 12 h of
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April 21, 2004:1368–74 Mitral Regurgitation and Primary Angioplastynset were randomized to balloon angioplasty  abciximab
ersus stenting  abciximab. Both the design and the
rincipal results of the CADILLAC trial have been re-
orted previously (18). In brief, the main exclusion criteria
ere cardiogenic shock, bleeding diathesis, known serum
reatinine 2.0 mg/dl, and baseline angiographic anatomy
ot eligible for stent implantation. Patients were pretreated
ith aspirin, a thienopyridine, heparin, and intravenous
eta-blockade in the absence of contraindications. Contrast
eft ventriculography in the 30° right anterior oblique view
as strongly recommended during the index procedure
efore coronary angiography to measure left ventricular
LV) systolic performance and end-diastolic pressure, assess
alvular function, exclude mechanical complications of
MI, and to confirm infarct location. The protocol speci-
ed that at least two consecutive non-premature ventricular
ontraction (PVC) or post-PVC beats must be present;
therwise, the injection should be repeated. Angiography
as then performed in multiple orthogonal views, followed
y PCI if the anatomy was appropriate for stent implanta-
ion, as previously described (18).
After PCI, medical therapy consisted of aspirin indefi-
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications
LV  left ventricle/ventricular
MR  mitral regurgitation
PCI  percutaneous coronary intervention
PVC  premature ventricular contraction
TIMI  Thrombolysis In Myocardial Infarction
able 1. Baseline Clinical Characteristics Stratified by the Severit
None
(n  1,726)
ge (yrs) 58.5 (50, 67)
ale gender 74.7%
iabetes mellitus 16.3%
ystemic hypertension 48.1%
ypercholesterolemia 38.7%
urrent smoker 44.3%
table angina pectoris 17.6%
rior myocardial infarction 14.2%
rior percutaneous intervention 11.1%
revious bypass surgery 2.0%
istory of cerebrovascular disease 2.7%
illip class 2 9.7%
hest pain to balloon inflation (h) 3.97 (2.88, 6.18)
edications prior to admission
Aspirin 27.2%
Beta-blockers 14.5%
ACE inhibitors or AR blockers 9.2%
Statins 11.7%
p  0.01 for moderate/severe mitral regurgitation vs. none/mild. Data are represen
ACE  angiotensin-converting enzyme; AR  angiotensin receptor.itely, a thienopyridine for one month after stent implan-
ation (optional in balloon angioplasty patients), and oral
ngiotensin-converting enzyme inhibitors and beta-blockers
f not contraindicated. Clinical follow-up extended for 12
onths. The primary end point was a composite of major
dverse cardiovascular events, consisting of death, disabling
troke, reinfarction, or repeat revascularization of the target
essel due to ischemia, as previously defined (18).
eft ventriculographic analysis. All angiograms were an-
lyzed at a central, independent core laboratory (the Car-
iovascular Research Foundation, New York, New York).
eft ventricular ejection fraction was calculated by the
rea–length method (19), and regional wall motion deter-
ined by the centerline chord method (20). Core laboratory
uantitative assessment of MR was not contracted. Mitral
egurgitation was assessed by the operator and divided into
our strata: none  no systolic regurgitation of contrast into
he left atrium; mild  partial opacification of the left
trium, which never equaled the extent of opacification of
he LV; moderate  complete opacification of the left
trium equal to that of the LV but clearing more quickly;
nd severe  complete opacification of the left atrium
reater than that of the LV in either systole or diastole. The
everity of MR was graded only if at least two consecutive
on-PVC or post-PVC beats were present.
tatistical analyses. Continuous variables are presented as
edians and interquartile ranges, and these were compared
sing the Kruskal-Wallis nonparametric test. Categorical
ata are summarized as proportions and compared using the
ikelihood-ratio chi-square test. Survival was estimated us-
ng Kaplan-Meier methodology and compared using the
og-rank test. Cox proportional hazards regression was used
o determine the independent predictors of one-year mor-
Mitral Regurgitation
itral Regurgitation
p Value
Mild
(n  192)
Moderate/Severe
(n  58)
62.0 (52, 72) 70 (62, 77) 0.0001
67.2% 46.6%* 0.0001
15.6% 20.7% 0.65
44.3% 60.3% 0.10
38.5% 29.3% 0.35
37.0% 22.4%* 0.0009
19.6% 10.5% 0.66
13.6% 12.1% 0.88
13.0% 8.6% 0.59
1.0% 5.2% 0.14
4.7% 5.2% 0.19
12.1% 25.0%* 0.0007
4.01 (2.90, 5.83) 3.83 (2.98, 7.13) 0.63
29.2% 36.2% 0.28
17.2% 31.0%* 0.002
10.9% 12.1% 0.58
14.1% 13.8% 0.57
median (25% and 75% interquartile ranges) or %.y of
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reatment assignment variables were selected using stepwise
election, entering those with a significant or borderline
nivariate association with mortality (p  0.10). Candidate
redictors of one-year mortality were: none versus mild
ersus moderate/severe MR, use of stent, use of abciximab,
ge, gender, Killip class (1 or 1), previous myocardial
nfarction, diabetes mellitus, hypertension, hypercholester-
lemia, baseline Thrombolysis In Myocardial Infarction
TIMI) flow grade 3, left anterior descending infarct artery,
hree-vessel disease, time from symptom onset to balloon
ngioplasty, creatinine clearance  60 cc/min, and ejection
raction. A p value of 0.05 was defined as significant.
ESULTS
aseline clinical characteristics. Left ventriculography
as performed during the index procedure in 1,976 (95%) of
he 2,082 randomized patients. Mitral regurgitation was
bsent in 1,726 patients (87.4%), mild in 192 patients
9.7%), moderate in 45 patients (2.2%), and severe in 13
atients (0.7%). For subsequent analyses, the moderate and
evere groups were combined into one strata. As seen in
able 1, patients with progressively more severe MR were
lder, were more often women, were less frequently current
mokers, and had higher Killip class on admission. Medi-
ation use before admission was similar in the three groups,
xcept that patients with progressively more severe MR
ere more likely to be taking beta blockers (Table 1).
ngiographic features and procedural outcomes. The
able 2. Baseline Angiographic Characteristics and Procedural O
None
(n  1,726)
ne-vessel disease 52.8%
wo-vessel disease 32.7%
hree-vessel disease 14.4%
jection fraction (%) 58 (49, 65)
nfarct zone regional wall motion (SD/chord)  1.30 (1.65, 0.8
nfarct vessel
Left anterior descending 35.8%
Left circumflex 17.7%
Right coronary 46.5%
Left main (protected) 0%
aseline
TIMI flow grade 3 23.1%
Diameter stenosis (%) 100 (75, 100)
tent(s) implanted 55.8%
bciximab administered 52.3%
inal
TIMI flow grade 3 95.8%
Diameter stenosis (%) 23 (17, 31)
p  0.04 for moderate/severe mitral regurgitation vs. none/mild. †p  0.001 for mo
5% interquartile ranges) or %.
SD  standard deviation; TIMI  Thrombolysis In Myocardial Infaraction.everity of MR strongly correlated with triple-vessel disease (nd LV dysfunction, as measured by both global ejection
raction and infarct zone regional wall motion (Table 2). Of
ote, AMI location was not associated with the severity of
R. There was a trend toward lower rates of baseline TIMI
ow grade 3 in the infarct vessel in patients with a higher
everity of MR. Stent and abciximab use were equally
istributed among the three groups. Procedural success, as
ssessed by final epicardial TIMI flow and lesion diameter
tenosis, was independent of the severity of MR.
linical outcomes. Corrective mitral valve surgery was
erformed in only one patient before discharge (a mitral
alve repair during bypass surgery in a patient with initially
ild MR). The duration of the hospitalization correlated
ith the severity of MR (3.5 vs. 3.9 vs. 4.1 days with no,
ild, and moderate/severe MR, respectively, p  0.006).
edications at the time of discharge were similar in the
hree groups except for greater use of angiotensin converting
nzyme inhibitors and receptor blockers in patients with
ore severe grades of MR (33.5%, 40.9%, and 50.0% in
atients with no, mild, and moderate/severe MR, respec-
ively, p  0.008).
As seen in Table 3 and Figure 1, survival was markedly
educed in patients with MR at both 30 days and one-year,
ith mortality progressively increasing with increasing MR
everity. Disabling stroke was significantly more common in
atients with moderate/severe MR at 30 days, but not at one
ear. By multivariate analysis, mild and moderate/severe MR
uring the index procedure were the two strongest indepen-
ent predictors of one-year mortality (Fig. 2). Survival in
atients with MR was unaffected by randomization to stenting
ersus balloon angioplasty, or abciximab versus no abciximab
es Stratified by the Severity of Mitral Regurgitation
Mitral Regurgitation
p Value
Mild
(n  192)
Moderate/Severe
(n  58)
42.7% 37.9%* 0.003
38.5% 27.6% 0.18
18.8% 34.5%† 0.0001
53 (39, 59) 51 (45, 68) 0.0004
1.44 (1.70, 1.08) 1.38 (1.76, 1.09) 0.02
40.6% 27.6% 0.17
18.8% 22.4% 0.63
40.1% 50.0% 0.20
0.5% 0% 0.96
19.7% 12.1% 0.09
100 (75, 100) 100 (73, 100) 0.54
63.5% 58.6% 0.12
54.2% 63.8% 0.21
96.3% 93.1% 0.57
22 (15, 30) 22 (17, 31) 0.35
/severe mitral regurgitation vs. none/mild. Data are represented as median (25% andutcom
4)
derateFig. 3).
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April 21, 2004:1368–74 Mitral Regurgitation and Primary AngioplastyISCUSSION
he principal findings of this analysis are: 1) in an AMI
opulation undergoing primary PCI (with the important
aveat that patients with cardiogenic shock were not en-
olled), MR at the time of the baseline procedure is evident
n 12.6% of patients; 2) the presence of MR is associated
ith advanced age, female gender, reduced LV function,
nd triple-vessel coronary artery disease, but not a specific
nfarct artery of electrocardiographic AMI location; and 3)
ven the presence of mild MR at baseline is a powerful
ndependent predictor of reduced survival after primary
CI.
Frequently, MR is present in the early phases of AMI,
hough its incidence is dependent upon the detection
echnique. Mitral regurgitation, within several days to one
Table 3. Clinical Outcomes Stratified by the S
None
(n  1,72
30-day events
Death 1.4%
Reinfarction 0.9%
Target-vessel revascularization 3.6%
Percutaneous intervention 2.5%
Bypass graft surgery 1.1%
Mitral valve repair/replacement 0%
Disabling stroke 0.1%
Composite adverse events 5.2%
Subacute thrombosis 1.0%
Moderate or severe bleeding 3.1%
1-year events
Death 2.9%
Reinfarction 2.6%
Target-vessel revascularization 13.6%
Percutaneous intervention 10.5%
Bypass graft surgery 3.4%
Mitral valve repair/replacement 0%
Disabling stroke 0.5%
Composite adverse events 16.8%
*p  0.001 for moderate/severe mitral regurgitation vs. no
none/mild. ‡p  0.002 for moderate/severe mitral regurgitaFigure 1. One-year survival stratified by the seek after AMI, has been reported to be present in 9% to
5% of patients by auscultation (11,21,22), and in 20% to
6% of patients by echocardiography (11,23,24). More
ecently, two angiographic studies have detected MR in
3% and 17.9% of patients within 7 h of admission for AMI
9,10), and in 19.4% of patients at a mean of four days (12).
he 12.6% incidence of MR present on the index angio-
ram during the early hours of evolving AMI in the present
tudy is consistent with these findings. The incidence would
ave been higher had patients not been excluded for
ardiogenic shock (25,26).
Compared to those without MR, patients with MR in
he CADILLAC trial were older and more often female,
imilar to previous reports (9,10,12). In addition, MR was
trongly associated with global and regional LV dysfunc-
ty of Mitral Regurgitation
Mitral Regurgitation
p Value
Mild
(n  192)
Moderate/Severe
(n  58)
3.7% 8.6%* 0.0001
0.5% 1.9% 0.67
2.7% 5.4% 0.64
1.6% 1.9% 0.68
1.1% 3.6% 0.22
0.5% 0% 0.99
0.5% 1.8%† 0.002
6.3% 15.5%* 0.004
0.5% 1.9% 0.69
2.7% 10.6%‡ 0.007
8.5% 20.8%* 0.0001
0.5% 1.8% 0.23
10.1% 19.2% 0.22
8.4% 13.8% 0.55
2.2% 5.6% 0.44
0.5% 1.8% 0.92
1.1% 1.8% 0.24
18.0% 34.5%* 0.001
ld. †p  0.01 for moderate/severe mitral regurgitation vs.
. none/mild.everi
6)
ne/mi
tion vseverity of baseline mitral regurgitation.
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Mitral Regurgitation and Primary Angioplasty April 21, 2004:1368–74ion, as well as with signs of clinical congestive heart failure
n admission, also consistent with earlier observations in
brinolytic studies (9,10,12). The extent of coronary artery
isease also correlated with the frequency and severity of
R, consistent with some (8,10,12), but not all (9) prior
eports. Of note, no relationship was present in the current
tudy between the specific infarct vessel and MR, whereas
ther investigators have reported the presence and severity
f MR to be related to either inferior/posterior (3,10,12) or
nterior (9) AMI location. These conflicting data likely
ndicate that in different patient populations the predomi-
ant mechanism of MR may involve either more or less
Figure 2. Multivariate pr
igure 3. Impact of randomization to stenting versus balloon angioplasty
bciximab (pooled regardless of stent use) on one-year mortality as a func
ransluminal coronary angioplasty; open bars  stent; striped bars  no abcixschemic papillary muscle dysfunction (3,8) versus valvular
ysfunction from LV dilation and/or dysynchronous myo-
ardial contraction (5,6,12). Numerous experimental studies
ave emphasized the importance of the geometry of the LV
or normal mitral leaflet coaptation (5–7).
The most important finding of this study is that the
resence of MR of any degree on the baseline left ventricu-
ogram during the immediate intervention was a powerful,
ndependent predictor of mortality after primary PCI for
MI. After multivariate adjustment for differences in base-
ine characteristics between patients with and without MR,
ven mild MR was as strong or stronger a predictor of
rs of one-year mortality.
led regardless of abciximab administration), and to abciximab versus no
f the severity of baseline mitral regurgitation. Solid bars  percutaneous(poo
tion oimab; checkered bars  abciximab.
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April 21, 2004:1368–74 Mitral Regurgitation and Primary Angioplastyortality than advanced age, renal insufficiency, and triple-
essel disease, independent from the degree of LV dysfunc-
ion. More severe MR was directly and independently
ssociated with an even higher risk of mortality than mild
R. These findings confirm and extend the results of
arlier investigations demonstrating incremental mortality
ith increasingly severe grades of MR in patients with AMI
reated predominantly with thrombolytic therapy (9,10,12).
f note, procedural success rates were similar in patients
ith and without MR. Moreover, neither stent implanta-
ion nor abciximab administration improved the poor prog-
osis of patients with MR. Thus, the existence and severity
f ischemic MR remains an important determinate of
ecreased survival even after successful primary PCI in AMI
sing contemporary reperfusion strategies.
The mechanisms by which MR may increase mortality
fter primary PCI for AMI cannot be answered by this
tudy. Altered filling pressures and volume overload with
esultant LV remodeling have both been directly related to
ate mortality after AMI (27–29). Associated regional in-
arct zone akinesis can serve as a nidus for LV mural
hrombus with subsequent stroke (30,31). Moreover, MR
esulting from papillary muscle rupture, although uncom-
on, usually results in cardiogenic shock and subsequent
igh mortality whether managed medically or with valve
urgery (32). However, mitral valve repair and/or replace-
ent was rarely performed in the non-shock patients
andomized in the CADILLAC trial, reflecting a low rate
f structural valvular damage in this series.
tudy limitations. This study is a post hoc analysis of
rospectively collected data. These findings thus identify
ssociations but do not confirm causality. However, they are
onsistent with previous reports and confirm the importance
f MR in the setting of AMI (independent of ejection
raction), even after successful primary PCI. In addition, the
nderlying cause of MR was not determined in this study,
nd whether or not its existence pre-dated the AMI is
nknown. The angiographic grading of MR is a semi-
uantitative measurement and may be at variance with
easured regurgitant volume index, particularly in patients
ith enlarged LVs in whom the degree of MR may be
nderestimated (33). Finally, MR was operator-assessed in
he present study, and thus interpretation bias cannot be
xcluded. Moreover, whether the extent of MR as evaluated
y core laboratory analysis would have been more or less
rognostically predictive is unknown. However, the fact that
perator-assessed MR provided such powerful prognostic
nformation in this study suggests that awareness of this
ondition may offer immediate “on-line” prognostic utility.
linical implications. Currently, the management of isch-
mic MR is not well defined. Previous longitudinal studies
ave suggested that the severity of MR may improve after
uccessful reperfusion with fibrinolytic therapy (34,35) and
rimary PCI (14–17). Oral vasodilator therapy has been
hown to reduce MR and LV end-systolic and end-diastolic
olumes, and it may improve clinical outcomes (28,29).acking randomized studies, mitral valve surgery for func-
ional MR, even when severe, cannot be routinely recom-
ended unless refractory heart failure or cardiogenic shock
evelops (1,36–38). At a minimum, however, the presence
f MR identifies patients at high risk, in whom close
utpatient follow-up is warranted, and who may benefit
rom aggressive adjunctive medical therapy.
eprint requests and correspondence: Dr. Gregg W. Stone,
he Cardiovascular Research Foundation, 5 East 59th Street, 6th
loor, New York, New York 10022. E-mail: gstone@crf.org.
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